← Back to Search

Other

Anesthesia Comparison for Coronary Artery Disease Surgery (ETOPRO Trial)

Phase 4
Recruiting
Led By Joseph Hinchey, MD
Research Sponsored by Hartford Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients scheduled for elective open coronary arteries bypass graft CABG surgery
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

ETOPRO Trial Summary

This trial will compare the effects of two drugs used to induce anesthesia in CABG surgery patients, to see which has better outcomes for hemodynamic support, ventilation, ICU & hospital stays, mortality, & readmission rates.

Who is the study for?
This trial is for patients who can communicate in English or Spanish, are scheduled for elective open coronary artery bypass graft (CABG) surgery, and have an ASA score of I-IV. It excludes those with emergency CABG needs, known allergies to etomidate or propofol, seizure disorders, current participation in competing studies, shock conditions, or chronic steroid use within the last 6 months.Check my eligibility
What is being tested?
The study compares etomidate and propofol as anesthesia induction agents during CABG surgery. Participants will be randomly assigned to receive one of these drugs. Researchers will monitor hemodynamic support needs, stability during and after surgery, ventilation time, ICU stay duration, hospital stay length plus mortality and readmission rates over six months.See study design
What are the potential side effects?
Potential side effects from etomidate may include adrenal insufficiency and muscle movements while propofol can cause low blood pressure or allergic reactions. Both drugs could affect heart rate and breathing requiring close monitoring.

ETOPRO Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for an elective open heart bypass surgery.

ETOPRO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Vasopressors dose expressed by Noradrenaline Equivalent dose [μg/kg/min]
Secondary outcome measures
Hospital Readmissions
Hospital length of stay
ICU length of stay
+3 more

ETOPRO Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: EtomidateExperimental Treatment1 Intervention
Etomidate as the principal hypnotic agent in a single bolus dose of 0.2-0.3 mg/kg along with 250mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.
Group II: PropofolActive Control1 Intervention
Propofol as the principal hypnotic agent in a single bolus dose of 50mg of propofol along with 250 mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Etomidate
2013
Completed Phase 4
~5870

Find a Location

Who is running the clinical trial?

Hartford HospitalLead Sponsor
133 Previous Clinical Trials
18,632 Total Patients Enrolled
4 Trials studying Coronary Artery Disease
1,340 Patients Enrolled for Coronary Artery Disease
Joseph Hinchey, MDPrincipal InvestigatorHartford Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit for participation in this experiment restricted to those over 35 years of age?

"Per the eligibility criteria for this clinical trial, prospective participants must range from 18 to 90 years old."

Answered by AI

Has Etomidate been sanctioned by the United States Food and Drug Administration?

"The safety of Etomidate has been established via a Phase 4 trial, thus it received the highest score on our scale - 3."

Answered by AI

Are there any opportunities for enrollment in this trial currently?

"Despite being posted on November 1st 2023, the clinicaltrials.gov database shows that this study has ceased recruitment at present time. However, 555 other trials are presently accepting patients for their own studies."

Answered by AI

Is it possible for me to join this medical experiment?

"This trial is searching for approximately 300 individuals with coronary artery disease and aged between 18 to 90."

Answered by AI
Recent research and studies
The LancetJournal
Etomidate Versus Ketamine for Rapid Sequence Intubation in Acutely Ill Patients: A Multicentre Randomised Controlled Trial
Jabre, Patricia, Xavier Combes, Frederic Lapostolle, Mohamed Dhaouadi, Agnes Ricard-Hibon, Benoit Vivien, Lionel Bertrand, et al.. 2009. “Etomidate Versus Ketamine for Rapid Sequence Intubation in Acutely Ill Patients: A Multicentre Randomised Controlled Trial”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(09)60949-1.
Critical Care MedicineJournal
Single-dose Etomidate Is Not Associated with Increased Mortality in ICU Patients with Sepsis
McPhee, Laura C., Omar Badawi, Gilles L. Fraser, Patricia A. Lerwick, Richard R. Riker, Ilene H. Zuckerman, Christine Franey, and David B. Seder. 2013. “Single-dose Etomidate Is Not Associated with Increased Mortality in ICU Patients with Sepsis”. Critical Care Medicine. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/ccm.0b013e318274190d.
clinicaltrials.govStudy
Etomidate Versus Propofol in CABG Surgery
Joseph Hinchey 2023. "Etomidate Versus Propofol in CABG Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06068764.
All > Coronary Artery Disease
~200 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top